IPO Report: TetraLogic Pharmaceuticals (TLOG)

Francis Gaskins  |

TetraLogic Pharmaceuticals ($TLOG) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics

Nine other operating companies scheduled IPOs for this week.. The full IPO calendar can be found at IPOpremium.

Manager, Joint managers: Oppenheimer & Co., Guggenheim Securities and Needham & Co.

Co-Managers: None. S-1 filed November 6, 2013

TLOG scheduled a $90 million IPO with a market capitalization of $270 million at a price range midpoint of $14, on Nasdaq for Thursday, November 21, 2013.


TLOG’s small molecule therepeutics mimic Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant.


Accumulated deficit


Valuation Ratios


Price /

Price /

Price /

Price /

% offered

annualizing Sept 9 mos

Cap (mm)





in IPO

TetraLogic Pharmaceuticals









TLOG has no revenue and no collaboration partners. It is in the phase 1 and phase 2 clincial trial stage. The rating on TLOG is neutral to avoid.

TLOG is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct.

TLOG’s clinical-stage product candidate,Birinapant, is currently being tested in Phase 1 and Phase 2 oncology clinical trials for multiple solid tumors and hematological malignancies. TLOG’s clinical trials of birinapant have enrolled over 275 subjects.

Clinical trials
TLOG’s lead program is colorectal cancer, or CRC, where it has substantially completed a Phase 1/2 clinical trial, and TLOG intends to start a randomized Phase 2/3 clinical trial in the second half of 2014.

Birinapant is also being tested in an ongoing Phase 1/2 clinical trial in various blood cancers. TLOG has started a Phase 1 clinical trial in myelodysplastic syndromes, or MDS, and, upon its completion, intends to start a randomized Phase 3 clinical trial in the second half of 2014.

TLOG also has an open Investigational New Drug Application, or IND, and intends to start a Phase 1/2 ovarian cancer clinical trial in 2013.

Beyond its work in cancer, TLOG is evaluating birinapant and other product candidates in pre-clinical studies as potential antiviral therapeutic agents, with the goal of starting an antiviral clinical program in the first quarter of 2015.

Intellectual property

In November 2003, TLOG entered into an exclusive license agreement with Princeton University, subsequently amended in June 2004, August 2006 and October 2006, which grants TLOG the rights to certain U.S. patents controlled by the university relating to SMAC-mimetic compounds, including birinapant, and a non-exclusive right to certain know-how and technology relating thereto.

In addition to its license of the Princeton University patents, TLOG owns more than 120 patents and patent applications worldwide, all relating to SMAC-mimetics and uses thereof.
Of these, four U.S. patents that TLOG owns have been granted with claims that cover birinapant as a new chemical entity.
In particular, TLOG has issued patents in the U.S. that specifically claim birinapant as a composition of matter, as well as patents that cover a class of compounds that encompass birinapant as a composition of matter and methods of using the class of compounds for inhibiting tumor growth or inducing apoptosis in a cell.

In the field of SMAC-mimetics, TLOG’s principal competitors in clinical development include Curis (Phase 1), Debiopharma (Phase 1) and Novartis (Phase 2).

Companies with earlier stage (discovery or pre-clinical studies) SMAC-mimetic programs include Astex Pharmaceuticals, or Astex, Bristol-Myers Squibb Company, or BMS, and Ensemble Therapeutics.

In addition to companies developing SMAC-mimetics, TLOG competes with pharmaceutical and biotechnology companies that are developing therapies or marketing drugs to treat indications that TLOG is targeting. FDA approved drugs for patients with advanced or metastatic CRC are: 5-fluorouracil, aflibercept, bevacizumab, capecitabine, cetuximab, irinotecan, leucovorin, oxaliplatin, panitumumab and regorafenib.

The companies marketing these drugs include Amgen, Bayer, BMS, Eli Lilly and Company, or Eli Lilly, Novartis, Pfizer Inc., Roche and Sanofi S.A., or Sanofi.

5% stockholders

HealthCare Ventures VII, L.P. 14.08%

Novitas Capital 7.97%

Quaker BioVentures and associates 7.33%

Latterell Venture Partners and associates 5.52%

Clarus Life Sciences II, LP 22.69%

Hatteras Venture Partners and associates 7.53%

Pfizer Inc. 7.56%

NexTech III Oncology, LPCI 5.65%

Use of proceeds

TLOG expects to net $80.8 million from its IPO. Proceeds are allocated as follows:

To advance the clinical and pre-clinical development of birinapant. Specifically, TLOG currently estimates that it will use $50 million of the net proceeds from this offering to fund its CRC program and $20 million to fund its MDS program.

The balance will be used for other clinical programs, working capital and general corporate purposes.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Discover: Trending Events

United Nations
Blockchain for Europe
Humanity 2.0
World Economic Forum


Symbol Name Price Change % Volume
TLOG TetraLogic Pharmaceuticals Corporation 0.05 -0.00 -7.73 1,000
BCBHF Caribbean Investment Holdings Ltd 0.46 0.00 0.00 0



Symbol Last Price Change % Change





















Blockchain in Fintech - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Financial Market Infrastructure

Trending Articles

  • No items found.